Sentence examples for bone metastasis in patients from inspiring English sources

Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer.

Bone scintigraphy is a prevailing diagnostic test for the detection of bone metastasis in patients with prostate cancer because of its high sensitivity, cumulative evidence for detection, and easy accessibility (Langsteger et al., 2016).

It is not clear whether an SUV obtained by skeletal SPECT/CT scans and analysed using the CGZAS method has any clinical and diagnostic value for the evaluation of bone metastasis in patients with prostate cancer.

In fact, Ra-223 dichloride is used for treatment of bone metastasis in patients with castration-resistant prostate cancer (CRPC) because bone metastasis causes skeletal-related events, such as bone pain and fractures, leading to deterioration of quality of life or death [5 7].

The presence or absence of bone metastasis in patients was determined by bone scintigraphy, and was confirmed by conventional radiography (X-ray) as necessary.

The ability of MRK-003, a specific γ-secretase inhibitor (GSI), to delay the onset of bone metastasis suggests that blocking Notch activation in the bone marrow microenvironment might prevent or reduce bone metastasis in patients with breast cancer.

As death in prostate cancer patients without bone metastasis will prevent the occurrence of bone metastasis in those patients, the events of death without bone metastasis will compete against the events of occurrence of bone metastasis.

In our series, we did not find bone metastasis in 23 patients with stage I esophageal squamous cell carcinoma, indicating that bone scan could be overlooked in patients with stage I esophageal squamous cell carcinoma in the future.

In our study, we did not find bone metastasis in 23 patients with stage I esophageal squamous cell carcinoma with a median follow-up of 1442 days, indicating that bone scan could be omitted in patients with stage I esophageal squamous cell carcinoma.

Determining whether SDF-1 levels predict bone metastasis in HCC patients will require further study.

Matrix metalloproteinase 2 tumor tissue expression is associated with increased risk of bone metastasis in BC patients.